Today Stories
Sandwich, Kent, UK / 23 October 2024 / In a bid to enable future success and growth, ten entrepreneurial life science and technology businesses have begun the immersive Discovery Spark programme, with a prize package worth over £50,000 up for grabs.
Based in Sandwich, Kent, Discovery Park is a leading science and innovation campus offering a range of impressive facilities for dynamic start-ups through to global corporations. Now in its third iteration, the Discovery Spark programme equips early stage life science and technology businesses with the skills and tools to lay healthy foundations in their business, refine their commercial strategy and achieve investor readiness.
The ten entrepreneurial businesses securing a coveted spot on this cohort and looking to advance their organisation a…
The Cambridge-GSK Translational Immunology Collaboration (CG-TIC) brings together GSK’s expertise in the science of the immune system, AI and clinical development with Cambridge’s complementary expertise
GSK is investing more than £50 million in the CG-TIC to further accelerate research and development in kidney and respiratory diseases
GSK plc (LSE/NYSE: GSK) announced it is investing £50 million into a major new five-year collaboration with the University of Cambridge and Cambridge University Hospitals, to accelerate research and development into immune-related diseases. The collaboration, which will be called the Cambridge-GSK Translational Immunology Collaboration (CG-TIC), builds on GSK and Cambridge University’s existing scientific relationship and will aim to find ways to more pre…
Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder
With 11,000 talented and passionate people bringing iconic brands to life, Opella poised to ignite new bold development journey
Sanofi to become a focused science-driven biopharma delivering innovative medicines and vaccines to patients
Sanofi 2024 business EPS guidance upgraded today
Paris, October 21, 2024. Sanofi and CD&R announce today a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella. This new step in Opella’s journey paves the way for the creation o…
Sanofi and Orano join forces to develop next-generation radioligand medicines
Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight against rare cancers and further accelerate the development of next-generation radioligand medicines.
Building on the expertise and radioligand pipeline of Orano Med, Sanofi and Orano will invest in a new entity, operating under the Orano Med brand, and focusing on the discovery, design, and clinical development of next-generation radioligand therapies (RLTs) based on lead-212 (212Pb) alpha-emitting isotopes. This agreement follows Sanofi’s announcement of an exclusive licensing agreement with…
CHICAGO, IL (October 15, 2024) – Advanced Clinical, a privately-held clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey, has been honored with the American Staffing Association’s Elevate Award for having one of the best job training programs in the U.S. staffing and recruiting industry.
“We are deeply honored to receive this recognition for our ACCEL Talent Development Program,” said Julie Ross, President and CEO of Advanced Clinical. “At the heart of our mission is the belief that empowering individuals with the right opportunities and skill sets can truly enhance lives. This award is a testament to the dedication and innovation of our team, who have worked tirelessly to create a supportive and…
Prestigious award honors top pharmaceutical facility projects each year; showcases impressive engineering feats and technological innovation
NORTH BETHESDA, Md., Oct. 14, 2024 /PRNewswire-PRWeb/ -- The International Society for Pharmaceutical Engineering (ISPE) has recognized Eli Lilly Kinsale Limited as the Overall Winner of the 2024 Facility of the Year Awards (FOYA) for its IE2b facility based in Kinsale, Ireland. The winner was announced and formally recognized during ISPE's FOYA Banquet and Awards Celebration held in conjunction with the 2024 ISPE Annual Meeting & Expo in Orlando, Florida. The vision for Eli Lilly's IE2b project was to marry innovative, advanced technologies into a first-of-its-kind hybrid manufacturing platform in order to optimize synthetic peptide production fo…
Bracknell, UK. 14th October 2024: PharmiWeb.Jobs, the leading global life sciences job board, is excited to announce the launch of its redesigned website for life science recruiters and talent acquisition teams. With new features, content, and improved navigation, the new site presents a one-stop-shop for anyone recruiting within the industry looking for ways to enhance their hiring and keep up with the latest industry trends.
As well as a more streamlined user experience, the new site includes a more in-depth overview of PharmiWeb’s history, mission, vision, and values, providing deeper insights into the company’s purpose and dedication to the life sciences. It also provides easier access to valuable resources including industry reports, previous and upcoming webinars, newsletter subscrip…
Enrollment completed ahead of schedule in the global IDE for Abbott's Volt™ PFA System
Global FOCALFLEX trial now underway for Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™
Advisor™ HD Grid X Mapping Catheter, Sensor Enabled™, receives U.S. Food and Drug Administration clearance, begins commercial launch
ABBOTT PARK, Ill., Oct. 10, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has achieved new major milestones to support the company's growing suite of pulsed field ablation (PFA) solutions in electrophysiology: early completion of enrollment in the VOLT-AF IDE Study supporting the Volt™ PFA System, and the launch of the FOCALFLEX trial to assess the company's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ (SE), which will be used in the treatment of pati…
BERLIN – October 7, 2024 – EVERSANA, a leading provider of global commercial services to the life sciences industry, today announced the continued growth of its European footprint with a new office in Berlin, Germany, Europe’s largest pharmaceutical market.
The office opening represents the company’s continued investment in global commercial operations, including expanded critical infrastructure and commercial launch services across Europe. The location is the latest addition to EVERSANA’s real estate portfolio, including office locations in more than fifteen countries worldwide. The new facility is located in the Carre am Schnikelplatz building in the heart of Berlin and will serve as a destination for employee and client meetings throughout the region.
“Over the years we have made smart…
AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidaemia. This asset further strengthens the company’s cardiovascular portfolio to help address the major risk factors driving chronic cardiovascular disease.
Under the terms of the agreement, AstraZeneca will receive access to CSPC’s pre-clinical candidate small molecule, YS2302018, an oral Lp(a) disruptor, with the aim of developing this as a novel lipid-lowering therapy with potential in a range of cardiovascular disease indications alone or in combination, including with the oral small molecule PCSK9 inhibito…
Company Launches Accelerator™ Drug Development, 360° Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) Services that highlight advanced capabilities to help pharmaceutical and biotech customers solve global health challenges with new medicines and vaccines
MILAN--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc., the world leader in serving science, will showcase its latest innovations enabling the molecule-to-medicine journey and host a series of sessions that feature industry developments during CPHI Milan 2024, Oct. 8-10, in Milan, Italy. Leaders and experts from the company will be present at conference booth #7B18 to discuss how Thermo Fisher is supporting biotechnology and pharmaceutical companies across indications, modalities, sizes a…
mAbxience, a Fresenius Kabi majority-owned group, and Teva Pharmaceuticals International have entered a second global licensing agreement for an anti PD-1 biosimilar candidate currently in development for the treatment of multiple oncology indications. The agreement covers global markets, including in Europe and the United States.
Fresenius Kabi, an operating company of Fresenius, continues to strengthen its biopharma business and strategic network through this new agreement, which builds on the solid foundation of the initial partnership with Teva. This directly underscores the companies’ mutual goal to provide cost-effective, high-quality biosimilar treatments that address critical unmet needs in oncology care. By leveraging expertise and resources, the collaboration continues to drive i…
The Almac Group has today announced an £11m investment and the creation of over 100 new jobs to expand its global analytical services capabilities.
Over the past 18 months, Almac Sciences and Almac Pharma Services have jointly made this significant investment to expand their existing analytical laboratories, technology and resource to meet ongoing global demand.
Almac employs over 700 highly skilled analysts working in regulatory approved GMP laboratories across five locations in Craigavon, UK; Charnwood, UK; Souderton, Pennsylvania; Athlone, Ireland and Dundalk, Ireland. Construction of new laboratory space at the company’s global Headquarters in Craigavon considerably increases overall capacity, while additional upgrades and development of existing labs across all sites mean Almac will…
Chiesi Group is making a strategic investment of €400 million to establish its new Biotech Center of Excellence in Parma.
The Center is designed to integrate the entire supply chain, enhancing innovation and production, while its seamless research-production integration will accelerate product development and autonomous production capacity.
Chiesi’s strategy aligns with EU priorities on innovation, security, and private R&D investment.
Parma (Italy), 30th September 2024 - Today, Chiesi Group, an international biopharmaceutical company focused on research, celebrates the operational launch of its Biotech Center of Excellence. This state-of-the-art facility is dedicated to developing and producing monoclonal antibodies, enzymes, and other proteins.
This facility is anticipated to be ou…
Global investigative sites recognize Parexel’s commitment to strong site relationships and patients
DURHAM, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been awarded the 2024 Society for Clinical Research Sites (SCRS) Eagle Award in the CRO category for the second consecutive year. This prestigious award, presented at the annual SCRS Global Site Solutions Summit held Sept. 27-29 in Hollywood, Fla., underscores Parexel’s dedication to fostering strong partnerships with investigative sites and advancing patient-guided clinical research.
"This recognition reaffirms our commitment to collaborating with sites, which is crucial for…
Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone can live a healthy and productive life, free from the preventable suffering, stigma, disability, and death caused by non-communicable diseases (NCDs). The start of the partnership was announced alongside the United Nations Global Assembly in New York.
NCDs are a major global health issue. These diseases, which are not transmitted from person to person, cause 41 million deaths each year, accounting for 74% of all deaths worldwide. With at least one in three people living with a NCD and half the world's population lacking essential health services, many are not receiving the care they need.
Within the broad category of NCDs, there are specific types known as Card…
Provides patients with certain chronic lung conditions and retained secretions added comfort, user-friendly touch screen and unique garment design options
Developed in consultation with clinicians and patients for an enhanced user experience
The Vest uses High Frequency Chest Wall Oscillation therapy, a therapy for which Hillrom, now part of Baxter, has been a pioneer and industry leader
BOSTON, Mass. - 2024-09-26
Baxter International Inc. (NYSE:BAX), a leading global medtech company, today unveiled its next generation airway clearance system, The Vest Advanced Pulmonary Experience (APX) System, at the North American Cystic Fibrosis Conference. The Vest APX System supports daily therapy for adults and children with certain chronic lung conditions and retained secretions. The system…
Inauguration of Angelika Amon research building in Vienna
Sustainable research building at a cost of EUR 60 million offers modern office and laboratory space
Over the past five years, Boehringer’s capital investments reached EUR 6.0 billion
Boehringer Ingelheim is one of the world's leading research-oriented pharmaceutical companies. The clinical pipeline is constantly being further developed, and Boehringer Ingelheim expects new approvals also in oncology in the coming years.
An important investment in the future is the new Angelika Amon Research Building, opened on September 25, in the presence of guests from politics and science. The modern and sustainable building offers ideal conditions for researchers on 11 floors, where 150 people work on promising therapeutic approaches agai…
New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a single patient sample on the high throughput molecular diagnostic analysers cobas 5800, 6800 and 8800.
TAGS has the potential to revolutionise testing for other infectious diseases in the future, by bringing high throughput customised syndromic panel testing to the routine clinical laboratory.
The first TAGS-based test to be made available, the cobas Respiratory flex, offers fast, efficient detection of up to 12 of the most common respiratory viruses with the flexibility for targeted testing, expediting accurate diagnosis, optimising antimicrobial use and saving time in the lab.
Basel, 24 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launc…
New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a single patient sample on the high throughput molecular diagnostic analysers cobas 5800, 6800 and 8800.
TAGS has the potential to revolutionise testing for other infectious diseases in the future, by bringing high throughput customised syndromic panel testing to the routine clinical laboratory.
The first TAGS-based test to be made available, the cobas Respiratory flex, offers fast, efficient detection of up to 12 of the most common respiratory viruses with the flexibility for targeted testing, expediting accurate diagnosis, optimising antimicrobial use and saving time in the lab.
Basel, 24 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launc…
